different response skov3 sw620 cell treatment cisplatin topotecan parameter ic half maximal effective concentration ec gi often use measure drug sensitivity 20,21,22. treat model cell line two drug different mechanism action cisplatin cause dna crosslinks topotecan inhibit topoisomerase i. use mt assay determine compound concentration require reach 50 maximum possible response treatment ic 50 reduction number viable cell gi calculate cisplatin topotecan ic value sw620 cell approximately 4 μm 21 nm respectively gi value similar ic value namely 6 μm cisplatin 26 nm topotecan fig 1. hand doseresponse curve obtain skov3 cell barely reach 50 reduction mark result gi 2 time higher ic 17 μm v 7 μm cisplatin 138 nm v 68 nm topotecan respectively indicate significant number viable cell leave even highest concentration drug fig 1. data suggest cytotoxic effect cisplatin topotecan skov3 cell le prominent sw620 cell mt assay data imply response different drug within one cell line either sw620 skov3 may similar term cell death proliferation arrest investigate process potentially involve druginduced effect perform pilot experiment sw620 skov3 cell treat cisplatin topotecan concentration correspond ic value use different selective inhibitor determine type cell death induce compound 25 08m qvdoph qvd pancaspasetargeting apoptosis inhibitor 12.5 08m chloroquine autophagy inhibitor 20 08m necrostatin1 ripk1targeting necroptosis inhibitor 2.5 08m ferrostatin1 ferroptosis inhibitor qvd inhibitor able partially restore number live sw620 cell treatment allow u assume apoptosis provide main contribution cell death cause cisplatin topotecan supplementary fig 1a therefore use qvd study cisplatin topotecan action model cell line furthermore lack prominent cell number recovery observe skov3 cell supplementary fig 1b suggest cytotoxic response cisplatin topotecan may weak thus support initial observation base gi value base result describe assume cisplatin cytotoxic effect sw620 cell presumably exert apoptosis activation investigate idea detail way treat cell 5 μm cisplatin presence absence 25 μm qvd compare cell viability data use mt livedead annexin vpi western blot assay fig 2 supplementary fig 2 3. agreement pilot experiment supplementary fig 1 mt assay demonstrate significant decrease viability cisplatintreated cell partially rescue upon addition qvd see fig 2a livedead assay confirm reduction number viable cell cisplatin treatment provide direct confirmation apoptosis indicate significant increase number dead cell prevent qvd fig 2b also verify livedead assay provide consistent detection live dead sw620 cell via confocal microscopic image analysis confirm calceinam ethd1 signal mutually exclusive correctly correspond viable dead cell supplementary fig 2. surprisingly addition qvd cisplatin result significant recovery calceinam signal despite clear inhibition cell death fig 2b observation imply cisplatininduced decrease sw620 viable cell number large extent facilitate via proliferation arrest result actual cell death also first discrepancy observe otherwise similar mt livedead assay next evaluate specific fraction treat cell use flow cytometry annexin vpi stain confirm cisplatin treatment induce apoptosis sw620 cell reveal majority cisplatintreated cell state early apoptosis fig 2c supplementary fig 3. fact agreement earlier suggestion cytostatic stressinducing action cisplatin prominent cytotoxic effect qvd able rescue cell early apoptosis late apoptosissecondary necrosis state cisplatininduced cell death involve various molecular mechanism include apoptosis necroptosis autophagy 23 24 evaluate level several program cell death biomarkers regulator use western blot fig 2d process caspase3 cleavage polyadpribose polymerase1 parp1 essential step apoptosis ripk1 phosphorylation require necroptosis sqstm1p62 degradation map1lc3b lipidation indicative autophagy detection cleave form caspase3 parp1 cell lysates incubation cisplatin demonstrate activation apoptotic pathway cisplatintreated sw620 cell 25 26. besides caspase3 parp1 activation western blot reveal cisplatin treatment result reduction sqstm1p62 level accumulation map1lc3bii fig 2d standard autophagosome marker generate conjugation cytosolic map1lc3bi phosphatidylethanolamine surface nascent autophagosomes 27,28,29,30. simultaneous treatment qvd cisplatin also result phosphorylation ripk1 kinase may indicate activation pronecroptotic machinery due caspase inhibition fraction cell state early necroptosis q1 area fig 2c negligible sample however inhibition cisplatininduced apoptosis qvd still result significantly larger fraction dead cell q2 area control sample imply cell undergo necroptotic death result describe demonstrate cisplatin treatment sw620 cell lead cell proliferation arrest induction apoptosis qvd treatment rescue cell early apoptosis cytostatic effect cisplatin dependent caspase activity therefore would incorrect interpret cisplatininduced reduction mt assay signal cytotoxic cytostatic complex without detail investigation use additional methodological approach sensitivity different cell line cytotoxic cytostatic effect drug vary seek determine detail viability evaluation technique give special attention order ass effect drug correctly achieve goal examine response sw620 skov3 cell treatment topoisomerase inhibitor topotecan similarly cisplatin treatment experiment describe mt livedead assay demonstrate incubation sw620 skov3 cell topotecan ic concentration 20 nm sw620 70 nm skov3 significantly decrease number viable cell fig 3a b. however remarkable addition qvd topotecan completely restore mt signal partially restore calceinam signal sw620 cell effect skov3 cell suggest topotecan induce caspasedependent apoptosis skov3 cell idea support comparison number dead cell detect use ethd1 stain sw620 cell display pattern similar one observe cisplatin treatment significant cell death induction topotecan alone abolish qvd addition significant difference experimental group skov3 cell strong evidence skov3 cell prominent resistance cytotoxic action topotecan cell line topotecaninduced decrease mt assay value consider purely cytostatic effect without relevant contribution cell death annexin vpi analysis confirm observation fig 4a topotecantreated sw620 cell display significant decline fraction live cell approximately 25 cell label apoptotic q2 q3 area time addition qvd clearly restore live cell fraction decrease content apoptotically alter cell expect base mt livedead assay result despite significant reduction number viable cell fig 3a b topotecantreated skov3 cell display weak apoptosisassociated change base flow cytometry fig 4a topotecan cause marginal 13 decrease relative content live cell main contribution annexin vpositive subpopulation skov3 cell provide cell early apoptosis gate q3 increase late apoptosis fraction negligible fig 4a confirm lack proapoptotic change skov3 cell use western blot detect low level cleave parp1 lack activate caspase3 fig 4b surprisingly level process caspase3 also low topotecantreated sw620 cell qvd still able prevent cell death suppose topotecan may induce apoptosis sw620 cell activation caspase caspase3 trigger fast degradation active form similarly cisplatin topotecan promote autophagy sw620 cell manifest map1lc3b lipidation decrease sqstm1p62 level however change ripk1 phosphorylation consistent difference autophagic necroptotic protein skov3 cell upon topotecan treatment fig 4b skov3 cell much resistant cytotoxic action topotecan decide check sensitivity cisplatinbased cell death induction use establish set experiment expect skov3 cell almost completely insensitive cytotoxic effect cisplatin reduction number viable cell cisplatin treatment due proliferation arrest fig 5. fact complete agreement earlier observation even highest concentration cisplatin could reduce number viable skov3 cell 40 control level due lack cell death fig 1. addition cisplatin treatment skov3 cell unable induce prominent autophagy necroptosisassociated protein change previously observe sw620 cell fig 2d 5d therefore conclude skov3 cell display susceptibility cytostatic action various drug may exhibit universal resistance cytotoxic \<SEP>0